Compare ANGI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | IKT |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.2M | 220.5M |
| IPO Year | 2017 | 2020 |
| Metric | ANGI | IKT |
|---|---|---|
| Price | $4.75 | $2.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $17.00 | $5.00 |
| AVG Volume (30 Days) | ★ 770.2K | 755.7K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $736,386,000.00 | N/A |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 47.60 | N/A |
| 52 Week Low | $4.26 | $1.33 |
| 52 Week High | $18.70 | $2.53 |
| Indicator | ANGI | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 62.29 |
| Support Level | $4.57 | $1.63 |
| Resistance Level | $6.52 | $2.53 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 22.76 | 73.42 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.